News archive

Scandinavian Biopharma continues to grow – 2016 was another successful year


2016 was another successful year with continued strong growth for Scandinavian Biopharma. For the distribution business, which are conducted through the subsidiary Scandinavian Biopharma Distribution, revenue growth landed at impressive 43%. At a group level the growth was 7 % in 2016 as revenues increased from 44,2 million SEK in 2015 to 47,3 million SEK […]

Our collaboration partner, Jan Holmgren, is awarded the world’s greatest vaccine prize


This week, Dr. Jan Holmgren received the 24th annual Albert B. Sabin Gold Medal Award in honor of his pioneering work in mucosal immunology and leadership in the development the world’s first oral cholera vaccine. Awarded annually since 1994, the Albert B. Sabin Gold Medal Award recognizes a researcher who has made extraordinary contributions in the […]

Scandinavian Biopharma enters into an exclusive agreement with Flynn Pharma for ViperaTAb


Scandinavian Biopharma today announces that the company has entered into an exclusive agreement with Flynn Pharma for the viper antivenom ViperaTAb. Under the new agreement, Scandinavian Biopharma will have exclusive rights to service and make ViperaTAb available for emergency use in the Nordics, Baltic States and Germany. “We are very pleased to strengthen our portfolio […]

Scandinavian Biopharma is expanding by hiring a PhD in cell- and molecular biology


We are happy to announce that Teresa Holmlund has joined us. Teresa has a PhD in cell and molecular biology and ten years of academic research experience studying molecular mechanisms in mitochondrial disease, cancer and severe congenital neutropenia. – It feels great to be a part of Scandinavian Biopharma. It’s really motivating to work with […]

All 450 participants starting from adults down to 6 months young infants are enrolled in our study in Bangladesh


One and a half year ago a phase I/II randomized, double-blind, placebo-controlled trial was started in Dhaka, Bangladesh. All 450 participants have now been enrolled and the last child received the vaccine this February. This clinical trial is the first important step toward showing that our vaccine can protect children in the developing world against […]

We are proud!


We are a part of the global movement to defeat diarrheal disease. That makes us proud!  

Etvax® was presented at VASE Conference


Last week scientists, public health professionals, immunization leaders, vaccine industry representatives, international donors, and other experts from across the globe met at PATHs VASE Conference. The common goal is to develop and introduce new enteric vaccines to defeat diarrhea. Our vaccine-candidate, Etvax®, was presented as the leading candidate in the field of ETEC. We, Scandinavian Biopharma, were […]

Our ETEC-story is told in ”European Biotechnology”


In the editorial hardback book ”European Biotechnology” we tell our story and describe our role within the life science/ biotech industry. What makes us unique, what is our goals and research collaborations? We tell the story about the ETEC vaccine that will be an important tool to battle diarrheal disease.         […]

ETVAX® was presented at ASTMH in Philadelphia


This week the 64th meeting of ASTMH (American Society of Tropical Medicine and Hygiene) was held in Philadelphia, USA. The annual meeting was a five-day educational conference that drew approximately 4,400 attendees. Our ETEC vaccine Etvax® was of cause on the agenda. Professor Svennerholm gave a talk about the great properties and development achievements of […]

Scandinavian Biopharma expands its product portfolio with an immunosuppressive drug


Scandinavian Biopharma recently entered into a distribution agreement with Neovii Pharmaceuticals AG, a fully integrated global biopharmaceutical organization based in Switzerland, and has expanded its product offering to include Neovii’s GRAFALON®. “With GRAFALON® we offer an immunosuppressive drug with a proven track record that is well established in the hospital market. This product is unique […]

Scandinavian Biopharma announces first patient vaccinated in the age-descending study in Bangladesh


On October 20, we began enrollment of a placebo-controlled Phase I/II trial where our enterotoxigenic Escherichia coli (ETEC) vaccine candidate will be tested for safety and immunogenicity in different age groups, including infants as young as six months of age. The study is being conducted under a US Investigational New Drug Application and will enroll […]

ETVAX® was presented as the lead candidate at CISTM14


The International Society of Travel Medicine (ISTM) holds its leading worldwide scientific congress biennially. Approximately 2,000 delegates from over 50 countries is attending. CISTM14 – 14th conference of the International Society of Travel Medicine has just been organized in Québec City, Canada. During the conference an up-to-date and broad-ranging program was presented by the key […]

Scandinavian Biopharma and PATH sign amendment to collaborative agreement to develop a vaccine against diarrhoeal disease


Enterotoxigenic Escherichia coli (ETEC) bacteria are responsible each year for around 400 million cases of diarrhoea and hundreds of thousands of deaths in low- and middle-income countries. Because of difficulties with diagnosis, mortality and morbidity estimates for ETEC are considered significant underestimates of the actual global public health burden. Children under the age of five […]

Impressive results in new Vaccine publication


Although ETEC is the most frequent bacterial cause of diarrhea in children in developing countries and the major cause of travelers’ diarrhea, no vaccine is yet available against ETEC disease. In a recently published article in Vaccine the clinical phase I results with our new oral vaccine against ETEC is presented. The objectives of this […]

Mapping the spread of diarrheal bacteria supports the design of our new vaccine


Every year hundreds of thousands of people die from diarrhea caused by ETEC bacteria. A study published in Nature Genetics describes how the University of Gothenburg, our collaborators, have mapped the spread of ETEC strains around the world. It provides key information about how pathogenic bacteria arise, which will be important for our vaccine currently […]

Radio Sweden reports about our vaccine


Our work of develop a new ETEC-vaccine has been highlighted in Radio Sweden, a non-commercial, independent public service radio broadcaster. The research project is a successful collaboration between the University of Gothenburg and PATH Vaccine Solutions. Enterotoxigenic Escherichia coli (ETEC) bacteria are responsible for some 400 million cases of diarrhoea annually and nearly half a […]

Our story is told in a new editorial book


In the books “Life Science in Sweden” and “European Biotechnology” the inspiring history of the life science/ biotech industry in Sweden and Europe are described and the technological innovations that have shaped it. It is Horn Publishing that has developed these new editorial hardback books profiling the medical biotech/biopharma industry throughout Europe. In both books […]

Scandinavian Biopharma receives 4.5 MSEK in funding from Vinnova


Scandinavian Biopharma via its subsidiary ETVAX receives 4.5 MSEK in funding from Vinnova for its project “One world one vaccine – to prevent ETEC diarrhea”. Vaccination is one of the most effective and cost-effective medical interventions there are. Preventing disease if possible is something we all strive for. More than one million children under five […]

Etvax® is now a registered trademark


Etvax® is now the registered trademark of Scandinavian Biopharma’s vaccine against diarrheal disease caused by enterotoxigenic E. coli bacteria (ETEC). Infections with ETEC bacteria are known to cause debilitating diarrhea in children living in endemic areas, and traveler’s diarrhea in travelers to such risk areas.  Etvax® is presently in Phase I/II clinical trials to document […]

Scandinavian Biopharma is expanding by hiring a pharmacist, PhD in microbiology


We are delighted to announce that Alma Brolund, pharmacist, PhD in microbiology has joined us. – It feels great to be a part Scandinavian Biopharma. I have previously worked to identify problems that bacteria causes. Now I will focus on preventing the diseases instead. It’s really motivating to work with the development of new vaccines […]

Scandinavian Biopharma – A Fast Growing Swedish biotech company


2013 was another successful year with continued strong growth for Scandinavian Biopharma. Revenue growth landed at impressive 78% in 2013, as revenues for the group increased from 16.5 million SEK in 2012 to 29.4 million SEK in 2013. In 2013 the distribution business, the group’s growth engine, accounted for 24 million in sales which represents […]

Scandinavian Biopharma and PATH sign collaborative development agreement after successful Phase I study of a novel vaccine candidate against diarrheal disease.


Travelers’ diarrhea is the leading cause of illness among international travelers to developing countries. Enterotoxigenic Escherichia coli (ETEC) bacteria are the primary cause of this disease. ETEC is also a major cause of diarrheal disease among children living in endemic countries, leading to over 400 million diarrheal episodes and approximately 300,000 deaths each year. Today […]

Phase I results will be presented at the International Conference on Mucosal Vaccines, Adjuvants & Delivery, in Copenhagen


In September results of the clinical Phase I study of our novel vaccine against diarrhea caused by ETEC will be presented at the International Conference on Mucosal Vaccines, Adjuvants & Delivery, in Copenhagen. Mucosal Vaccines, Adjuvants and Delivery is a three day conference (25-27 September) and its key focus will be on the requirements and […]

Scandinavian Biopharma announces successful results in placebo-controlled Phase I study of an oral, inactivated vaccine against diarrhea for travelers and children in developing countries


Travelers’ diarrhea is the leading cause of illness among international travelers to developing countries. Enterotoxigenic Escherichia coli (ETEC) bacteria are the primary cause of this disease. About 65 million people travel from industrialized countries to high-risk areas in the developing world. Of these, 30 to 50 percent, or approximately 27 million people, may experience at […]

New employee hired to meet the Nordic market need


An increased interest in our products on the Nordic market is now resulting in entering the Danish market with our immunoglobulin’s. In order to provide our Danish customers better and faster service the company needs to expand. Scandinavian Biopharma is therefore pleased to announce the recruitment of Stefan Einarsson.  Stefan has extensive experience in the biotech/pharmaceutical […]

Preclinical studies of the new oral Traveler’s diarrhea vaccine shows that it is safe and immunogenic


Results from preclinical evaluation of the new multivalent, oral Traveler’s diarrhea vaccine was recently published.  The vaccine, consisting of four inactivated E. coli strains and the ETEC-based B subunit protein LCTBA, was studied for immunogenicity and safety in mice. The optional co-administration of the vaccine with a nontoxic oral adjuvant (dmLT) was also studied. The […]

Scandinavian Biopharma through its subsidiary ETVAX continues clinical development


A clinical phase-I, randomized, placebo controlled, double-blinded study of the final composition vaccine, comprising 120 healthy volunteers is presently ongoing (study # OEV-121). All volunteers have been fully immunized and immunological analyses are ongoing. The study is designed to measure safety and immunogenicity of the vaccine when given either alone or in combination with the […]

Pressrelease – Scandinavian Biopharma announces positive results from its phase I study of a traveler’s diarrhea vaccine


A clinical phase-I study of the company’s new oral traveler’s diarrhea vaccine was recently successfully completed. The vaccine was shown to be safe and well tolerated by the study participants. The prototype vaccine also elicited an intestinal immune response to the vaccine components, in line with what is expected for a protective effect.

The results are very encouraging. A new clinical phase-I study to document the safety and immunogenicity of the final composition vaccine has been initiated.

PerioPruvTM-Point of Care Rapid test for Periodontal Infection


PerioPruvTM-, a point of care rapid test for detection of active periodontal infection, was launched at the Dental Hygenist Days Meeting in Karlstad, Sweden, 22-24 April 2012. The product gained much interest from the participants.

Statens Serum Institut (SSI), Denmark has appointed Scandinavian Biopharma Distribution


Statens Serum Institut (SSI), Denmark has appointed Scandinavian Biopharma Distribution as local representative in Sweden for its products.